Macquarie Group Ltd. cut its stake in Hologic Inc. (NASDAQ:HOLX) by 60.1% during the second quarter, Holdings Channel reports. The fund owned 14,900 shares of the company’s stock after selling 22,400 shares during the period. Macquarie Group Ltd.’s holdings in Hologic were worth $516,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also made changes to their positions in HOLX. State Street Corp increased its position in shares of Hologic by 26.4% in the first quarter. State Street Corp now owns 10,295,836 shares of the company’s stock valued at $355,210,000 after buying an additional 2,150,544 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Hologic by 8.1% in the second quarter. Vanguard Group Inc. now owns 26,537,173 shares of the company’s stock valued at $918,185,000 after buying an additional 1,992,898 shares during the last quarter. Wedge Capital Management L L P NC acquired a new position in shares of Hologic during the second quarter valued at approximately $48,888,000. Old Mutual Global Investors UK Ltd. increased its position in shares of Hologic by 276.7% in the second quarter. Old Mutual Global Investors UK Ltd. now owns 1,818,296 shares of the company’s stock valued at $62,913,000 after buying an additional 1,335,551 shares during the last quarter. Finally, Highbridge Capital Management LLC acquired a new position in shares of Hologic during the second quarter valued at approximately $45,302,000. 94.51% of the stock is currently owned by institutional investors and hedge funds.
Hologic Inc. (NASDAQ:HOLX) opened at 38.76 on Wednesday. Hologic Inc. has a 1-year low of $31.84 and a 1-year high of $41.66. The firm has a market capitalization of $10.75 billion, a P/E ratio of 42.73 and a beta of 1.03. The stock’s 50 day moving average is $38.33 and its 200-day moving average is $35.98.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, July 27th. The company reported $0.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.03. The firm earned $717.40 million during the quarter, compared to analysts’ expectations of $703.66 million. Hologic had a net margin of 9.39% and a return on equity of 26.25%. The business’s revenue was up 3.4% on a year-over-year basis. During the same period last year, the company earned $0.43 earnings per share. Analysts forecast that Hologic Inc. will post $1.94 EPS for the current year.
HOLX has been the topic of several recent analyst reports. Piper Jaffray Cos. set a $40.00 target price on Hologic and gave the stock a “hold” rating in a report on Monday, July 25th. They noted that the move was a valuation call. Barclays PLC upgraded shares of Hologic from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $42.00 to $44.00 in a research report on Friday, September 23rd. Evercore ISI upgraded shares of Hologic from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $38.00 to $42.00 in a research report on Thursday, July 28th. Canaccord Genuity set a $45.00 price objective on shares of Hologic and gave the stock a “buy” rating in a research report on Thursday, July 28th. Finally, Jefferies Group boosted their price objective on shares of Hologic from $42.00 to $43.00 and gave the stock a “buy” rating in a research report on Thursday, July 28th. Seven research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Hologic presently has an average rating of “Buy” and an average price target of $42.47.
In other news, Director Nancy Leaming sold 8,179 shares of Hologic stock in a transaction dated Thursday, July 21st. The shares were sold at an average price of $37.00, for a total transaction of $302,623.00. Following the completion of the transaction, the director now directly owns 67,140 shares in the company, valued at $2,484,180. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.84% of the company’s stock.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.